What is 3Daughters?
3Daughters is a clinical development company dedicated to advancing evolutionary healthcare for women, addressing critical areas where cutting-edge research and innovation are urgently needed. The company's core mission is to resolve significant, often neglected, health issues affecting women. A primary focus for 3Daughters is the radical transformation of the IUD market by tackling the major barrier to adoption: insertion pain.
How much funding has 3Daughters raised?
3Daughters has raised a total of $6.7M across 1 funding round:
Angel/Seed
$6.7M
Angel/Seed (2024): $6.7M with participation from University of Massachusetts - Amherst, Thairm Bio, Argosy Foundation, and Wexford Science & Technology
Key Investors in 3Daughters
University of Massachusetts - Amherst
The University of Massachusetts Amherst, a public research institution, is investing in 3Daughters, indicating a potential focus on academic research and innovation in healthcare.
Argosy Foundation
The Argosy Foundation, a private family foundation, supports programs that enhance society through creative solutions, suggesting alignment with 3Daughters' mission to address neglected health issues.
Wexford Science & Technology
Wexford Science & Technology, known for developing environments that foster innovation and collaboration with research institutions, likely sees strategic value in 3Daughters' advancements in women's healthcare.
What's next for 3Daughters?
With the recent major strategic investment, 3Daughters is poised to accelerate its development pipeline and market penetration. This substantial capital infusion is expected to fuel further research and innovation in women's healthcare, particularly in addressing the pain associated with IUD insertion. The company's focus on evolutionary healthcare suggests a long-term vision for improving women's health outcomes through novel solutions.
See full 3Daughters company page
